# Optimizing Pazopanib Exposure in RCC Patients

> **NCT02089802** · PHASE2 · TERMINATED · sponsor: **Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.** · enrollment: 6 (actual)

## Conditions studied

- Locally Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT02089802
- **Lead sponsor:** Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02-25
- **Primary completion:** 2016-03-22
- **Final completion:** 2016-03-22
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Early termination due to lack of recruitment
- **Last updated:** 2017-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089802, "Optimizing Pazopanib Exposure in RCC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02089802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*